Sandbox 127

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 40: Line 40:
== PBP2a and Ceftobiprole ==
== PBP2a and Ceftobiprole ==
- 
-
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
 
-
neither bound nor inhibited by β-lactams. Recently, two cephalosporins – <scene name='36/365380/Ceftobiprole/23'>ceftobiprole</scene> and
 
-
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
 
-
inhibit PBP2a because additional chemical groups at the <scene name='36/365380/Ceftobiprole/12'>R2</scene> position of the cephalosporin backbone are able to interact with additional amino acid residues in PBP2a; specifically
 
-
<scene name='36/365380/Ceftobiprole/22'>Tyr446 and Met641</scene>. As a result of its tighter binding to PBP2a, ceftobiprole is able to more
 
-
efficiently react with the serine active site residue and therefore inhibit the activity of
 
-
PBP2a.
 
- 
- 
- 
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
neither bound nor inhibited by β-lactams. Recently, two cephalosporins –
neither bound nor inhibited by β-lactams. Recently, two cephalosporins –
-
<scene name='37/372724/Ceftobiprole/1'>ceftobiprole</scene> and
+
<scene name='37/372724/Medicine_interaction/4'>cefobiprole</scene> and
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
inhibit PBP2a because additional chemical groups at the
inhibit PBP2a because additional chemical groups at the
-
<scene name='37/372724/Ceftobiprole/7'>R2</scene>
+
<scene name='37/372724/Medicine_interaction/3'>R2</scene>
position of the cephalosporin backbone are able to interact with additional amino acid
position of the cephalosporin backbone are able to interact with additional amino acid
residues in PBP2a; specifically
residues in PBP2a; specifically
-
<scene name='37/372724/Tyr446_and_met641_label/2'>Tyr446 and Met641</scene>.
+
<scene name='37/372724/Medicine_interaction/2'>Tyr446 and Met641</scene>.
-
As a result of ceftobiprole <scene name='37/372724/R2_interaction/4⅝'>tighter binding</scene> to PBP2a as highlighted in green , <scene name='37/372724/Ceftobiprole_in_cpk/1'>the medicine</scene>, shown as colors of the atom types ([[CPK]]), is able to more efficiently react with the serine active site residue and therefore inhibit the activity of PBP2a.
+
<scene name='37/372724/Medicine_interaction/1'>The medicine</scene> shown as colors of the atom types ([[CPK]]) is able to more efficiently react with the serine active site residue and therefore inhibit the activity of pbp2a as a result of ceftobiprole <scene name='37/372724/R2_interaction/6'>tighter binding</scene> to pbp2a. unlike penicillin, this results in inhibition of pbp2a
-
 
+
-
 
+
-
 
+
-
<scene name='37/372724/Medicine_interaction/4'>cefobiprole</scene>
+
-
<scene name='37/372724/Medicine_interaction/3'>R2</scene>
+
-
<scene name='37/372724/Medicine_interaction/2'>Tyr446 and Met641</scene>
+
-
<scene name='37/372724/Medicine_interaction/1'>the medicine</scene>
+
-
<scene name='37/372724/R2_interaction/6'>tighter binding</scene>
+

Revision as of 17:51, 15 August 2013

Drag the structure with the mouse to rotate
Personal tools